Get started
SAREPTA THERAPEUTICS INC COM USD0.0001SAREPTA THERAPEUTICS INC COM USD0.0001SAREPTA THERAPEUTICS INC COM USD0.0001

SAREPTA THERAPEUTICS INC COM USD0.0001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

0L35 trade ideas

Sarepta Therapeutics could move big on Monday All eyes and ears will be focused this week on the JPM20 conferences at which SRPT is expected to possibly give a pre-announcement on earnings and a Drug Trial Update on Monday. These events can move a stock very fast and the option market is already implying a 6.5% move in the stock. Short interest in the company is high at !7% which could led to quiet a rally on any positive updates. Average Recommendation: BUY Average Target Price: 196.86 23 Buy 2 Overwight 1 Hold 0 Sell Company Profile Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
NASDAQ:SRPTLong
by Bullishcharts
1
$SRPT Next trade for Sarepta Therapeutics Entry level $146 = Target price $158 = Stop loss $142 We have been covering this long form the $80 region after a massive selloff as a result of FDA issues but today the company received a boost which is detailed below. Roche enters $1.15 billion licensing deal for Sarepta gene therapy ZURICH (Reuters) - Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States. Roche will make an upfront payment of $750 million in cash and $400 million worth in equity at closing for Sarepta's investigational micro-dystrophin gene therapy SRP-9001 that is currently in clinical development, the Swiss drugmaker said in a statement on Monday. In addition, Sarepta is eligible to receive up to $1.7 billion in regulatory and sales milestones, plus royalties on net sales, Roche said, adding the agreement was expected to close in the first quarter of 2020. Sarepta will continue to be responsible for the clinical development and manufacturing of SRP-9001 while sharing global clinical development costs equally with Roche. DMD is a rare degenerative neuromuscular disorder, affecting about one in 3,500-5,000 male births worldwide and causing severe progressive muscle loss and premature death, Roche said. Earlier this month, Sarepta gained U.S. approval for another DMD drug, Vyondys 53. Sourse Reuters
NASDAQ:SRPTLong
by Bullishcharts
$SRPT Sarepta Therapeutics Halted Afterhours. Sarepta Therapeutics (NASDAQ:SRPT) +23.4% after-hours on news the Food and Drug Administration granted accelerated approval to the company's Vyondys 53 (golodirsen) injection to treat a rare Duchenne muscular dystrophy mutation. In making its decision, the FDA says it considered the potential risks associated with the drug, the life-threatening and debilitating nature of the disease and the lack of available therapy. As part of the accelerated approval process, the FDA requires SRPT to conduct a clinical trial to confirm the drug's clinical benefit. Source seeking alpha Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
NASDAQ:SRPTLong
by Bullishcharts
1
$SRPT SAREPTA grinding higher, gap approaching Hopefully you followed our previous winning trades on SRPT and having banked some nice gains. The next trade setup is to trade the gap with a entry level @ $16.85 and a gap fill target @ $119. Local rare disease drugmaker Sarepta Therapeutics Inc. is expanding its efforts in the gene therapy field, signing a deal this week with a North Carolina startup to develop up to eight new treatments. Sarepta (Nasdaq: SRPT) will pay Durham-based StrideBio Inc. $48 million upfront for four potential drugs, with additional milestone payments, in the deal announced Thursday. The Cambridge company also gets an exclusive option to partner on another four drugs for an additional $42.5 million, plus milestone payments, and will invest in StrideBio’s next financing round, according to a press release. Under the deal, StrideBio will conduct initial research on the first four treatments, which are for Rett syndrome, Dravet syndrome, Angelman syndrome and Niemann-Pick. Earlier this year, Sarepta expanded its reach beyond rare disease drug development, announcing in August it would develop a gene-targeting treatment for multiple sclerosis, a disease that affects close to 1 million adults in the U.S. The early focus of the StrideBio collaboration is on four rare central nervous system diseases. Sarepta will also have exclusive rights to license four further potential drugs from StrideBio’s pipeline under the deal. The move puts Sarepta in competition with Novartis (NYSE: NVS), whose subsidiary AveXis is developing a treatment for the rare neurological disorder Rett Syndrome, as well as local startup Stoke Therapeutics (Nasdaq: STOK). Sarepta made its name by developing the first treatment for the rare disease Duchenne muscular dystrophy. It is currently developing treatments that insert healthy genes into a person’s system for Duchenne and another form of muscular dystrophy. But Sarepta’s gene therapy for Duchenne was put under the microscope in August when a 7-year-old trial participant suffered a potentially life-threatening complication, which did not require any pause in or changes to the clinical trial. This is not StrideBio’s first deal with a Massachusetts drugmaker. Earlier this year, the privately held company signed a collaboration agreement with Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) to develop gene therapies for the rare genetic disease Friedreich's Ataxia and two other undisclosed disease targets. Takeda is in the process of relocating its U.S. headquarters from Illinois to Massachusetts. The StrideBio collaboration will also involve addressing a industry-wide question around the possibility and effectiveness of giving patients a second, third or subsequent doses. Researchers have questioned whether the body’s immune cells will begin to recognize and fight the viruses used to deliver gene therapies. Source Bostonnews Short squeeze potential with a very high 22.14% short interest. Company profile Sarepta Therapeutics , Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
NASDAQ:SRPTLong
by Bullishcharts
$SRPT Reversal trade in SareptaEntry level $98 = Target price $125 (long term) $108 (short term) Looks like a strong reversal setup, the macd is about to cross while the histogram is also in the process of turning green. Bullish 7&12 MA cross imminent. Resistance as per the chart. Earnings article by Barrons. Earnings at the biotech firm Sarepta Therapeutics fell short of expectations in the third quarter of the fiscal year, but sales of a key drug, Exondys, were in line with Wall Street estimates. The company reported earnings after the market closed on Thursday. The stock was steady in premarket trading on Friday. Sarepta (ticker: SRPT) reported a loss of $1.14 per share, $0.22 worse than the Wall Street consensus reported by S&P Capital IQ. But the company reported sales of $99 million for Exondys 51, its treatment for Duchenne’s muscular dystrophy treatment. Analysts tracked by FactSet had expected $96.6 million. “We think that Sarepta continues to make good progress on key objectives, including manufacturing, clinical trial enrollment of its gene therapy DMD study, and dose escalation for limb girdle gene therapy,” wrote Cantor Fitzgerald analyst Alethia Young in a Thursday note. The back story. Shares of Sarepta are down 14.4% this year. Shares fell sharply in August and September after the Food and Drug Administration declined to provide accelerated approval for a Duchenne muscular dystrophy treatment called golodirsen. What’s new. Sarepta nodded to the setbacks in its earnings statement, but said it was progressing. “While not without its challenges, 2019 has been one marked by a significant advancement of our platform,” said Doug Ingram, the company’s president and CEO. “We continued to exceed revenue expectations, built our pipeline and advanced our programs, reported additional positive and validating clinical data, advanced our manufacturing strategy.” The company reported that it has $1.1 billion in cash, cash equivalents, and investments. “We think that Sarepta remains well-capitalized,” wrote Cantor’s Young. The company highlighted its continuing gene therapy programs, including one for Limb-girdle muscular dystrophy diseases. “SRPT’s multiple gene therapy programs are making incremental steps toward commercialization,” wrote SVB Leerink’s Joseph Schwartz. Looking ahead. Cantor’s Young noted that Sarepta had little to say on golodirsen. “Mum is the word on golodirsen path forward, for which we think it’s probably fair to keep expectations low,” Young wrote. “We expect the company to provide an update when it has conclusive details. For the most part, we think that golodirsen expectations are out of the stock.” Shares of Sarepta were down 0.1% in premarket trading on Friday. Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com
NASDAQ:SRPTLong
by RedHotStocks
1
$SRPT Nomura sees 150% upside in Sarepta.Nomura $230 price target Sarepta analyst commentary at Nomura Instinet Sarepta has 'signficant upside catalysts ahead,' says Nomura Instinet. Nomura Instinet analyst Christopher Marai sees "significant upside catalysts ahead into mid-2020" for Sarepta Therapeutics. Ahead of the company's Q3 results on November 7 he keeps a Buy rating on the shares with a $230 price target. The analyst thinks Golodirsen's Complete Response Letter will likely be resolved in the near-term and that Sarepta's "valuation floor" is based on its current exon skipping platform. Source Thefly High Call options traded pre earnings. Indicators bullish and volume increasing. Short squeeze potential with a very high 22.14% short interest. Company profile Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
NASDAQ:SRPTLong
by Bullishcharts
$SRPT Sarepta Therapeutics owes its investors, big time.Possible short term breakout in SRPT above $89 with $96 as a 1-2-1 Fibonacci extension target. This may be a contrarian trade but maybe sentiment and expectations are so poor it presents a good short squeeze opportunity. Short interest is high at 21% and increased since the July disappointment. The average analysts price target is $186 and a BUY rating which is a 100% upside expectation. Company profile Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
NASDAQ:SRPTLong
by RedHotStocks